Meeting
2021 ASCO Annual Meeting
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
Authors
Fangchao Zheng
National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Fangchao Zheng , Feng Du , Yongsheng Wang , Xue Wang , Jiayu Wang , Jian Yue , Fei Ma , Ying Fan , Binghe Xu , Peng Yuan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01150513
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 529)
DOI
10.1200/JCO.2021.39.15_suppl.529
Abstract #
529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
First Author: Jessica N. Snider
Poster
2023 ASCO Annual Meeting
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer: A single-center, randomized, controlled, phase-II clinical study.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring